Related Experiment Video
Updated: Jul 23, 2026

08:17
Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo
Published on: September 22, 2017
19.2K
Characterization of Retinal Microvascular Abnormalities in Birdshot Chorioretinopathy Using OCT Angiography
Aman Kumar1, Alexander Zeleny1, Sunil Bellur1
1National Eye Institute, National Institutes of Health, Bethesda, Maryland.
Ophthalmology Science
|August 21, 2024
Summary
Birdshot chorioretinopathy (BCR) shows reduced retinal microvascular density (VD) on OCT angiography, correlating with disease duration. This VD may serve as a biomarker for monitoring BCR severity and progression.
Area of Science:
- Ophthalmology
- Medical Imaging
- Retinal Vascular Diseases
Background:
- Birdshot chorioretinopathy (BCR) is a posterior uveitis affecting the retina.
- Understanding retinal microvascular changes in BCR is crucial for disease management.
Purpose of the Study:
- To characterize retinal microvascular changes in BCR using Optical Coherence Tomography Angiography (OCTA).
- To assess the correlation between microvascular alterations and disease progression.
Main Methods:
- Retrospective analysis of OCTA images from 53 eyes with BCR and 110 control eyes.
- Assessment of superficial capillary plexus (SCP) and deep capillary plexus (DCP) for microvascular abnormalities.
- Measurement of vessel density (VD) and foveal avascular zone (FAZ) area, with longitudinal analysis in a subset of patients.
Main Results:
- BCR eyes exhibited reduced whole-image and extra-foveal VD in both SCP and DCP compared to controls (P < 0.0001).
- Enlarged FAZ area was observed in the DCP of BCR eyes (P = 0.0008).
- Decreased VD correlated with worsening visual acuity and was associated with disease duration, age, and treatment status.
Conclusions:
- Reduced retinal microvascular density is a significant finding in BCR.
- Quantifying VD may serve as a valuable biomarker for monitoring BCR severity and progression.
- Further longitudinal studies are needed to confirm the utility of VD in tracking disease and treatment response.

